HMGCR and metabolic disease: In our PheWAS results (Table 1), we found a validation signal - increased risk of lipoprotein disorders - suggesting our candidate SNP p. Ile638Val is behaving in vivo as an HMG CoA reductase activator, thus having the opposite effect of simvastatin, which functions as an HMG CoA reductase inhibitor.